ACE-inhibition induces a cardioprotective transcriptional response in the metabolic syndrome heart

Sci Rep. 2018 Nov 1;8(1):16169. doi: 10.1038/s41598-018-34547-9.

Abstract

Cardiovascular disease associated with metabolic syndrome has a high prevalence, but the mechanistic basis of metabolic cardiomyopathy remains poorly understood. We characterised the cardiac transcriptome in a murine metabolic syndrome (MetS) model (LDLR-/-; ob/ob, DKO) relative to the healthy, control heart (C57BL/6, WT) and the transcriptional changes induced by ACE-inhibition in those hearts. RNA-Seq, differential gene expression and transcription factor analysis identified 288 genes differentially expressed between DKO and WT hearts implicating 72 pathways. Hallmarks of metabolic cardiomyopathy were increased activity in integrin-linked kinase signalling, Rho signalling, dendritic cell maturation, production of nitric oxide and reactive oxygen species in macrophages, atherosclerosis, LXR-RXR signalling, cardiac hypertrophy, and acute phase response pathways. ACE-inhibition had a limited effect on gene expression in WT (55 genes, 23 pathways), and a prominent effect in DKO hearts (1143 genes, 104 pathways). In DKO hearts, ACE-I appears to counteract some of the MetS-specific pathways, while also activating cardioprotective mechanisms. We conclude that MetS and control murine hearts have unique transcriptional profiles and exhibit a partially specific transcriptional response to ACE-inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage*
  • Animals
  • Atherosclerosis / drug therapy
  • Atherosclerosis / etiology
  • Atherosclerosis / genetics*
  • Atherosclerosis / physiopathology
  • Cardiotonic Agents / administration & dosage
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / genetics*
  • Cardiovascular Diseases / physiopathology
  • Disease Models, Animal
  • Heart / drug effects
  • Heart / physiopathology
  • Humans
  • Metabolic Networks and Pathways / genetics
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / drug therapy*
  • Metabolic Syndrome / genetics
  • Metabolic Syndrome / physiopathology
  • Mice
  • Mice, Knockout
  • Obesity / drug therapy
  • Obesity / genetics
  • Obesity / physiopathology
  • Peptidyl-Dipeptidase A / genetics
  • Receptors, LDL / genetics*
  • Transcriptome / drug effects
  • Transcriptome / genetics

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Cardiotonic Agents
  • Receptors, LDL
  • Peptidyl-Dipeptidase A